Skip to main content
    G

    Gilead Sciences Inc (GILD)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $167.58
    -0.50 (-0.30%)

    Market Cap: $208.48B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Gilead Sciences Inc (GILD) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Gilead Sciences reported revenue of $29.44B for the fiscal year ended Dec 31, 2025, up 2.4% from the year before. That year, net income was $8.51B with a net margin of 28.9%, operating cash flow was $10.02B and free cash flow was $9.46B. The quarter ended Sep 30, 2026 had revenue of $8.30B and net income of $2.43B.

    Revenue and Margins

    The operating margin was 34.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from $30.39B, a compound annual decline of 0.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$29.44B+2.4%78.8%34.0%28.9%
    Dec 2024$28.75B+6.0%78.3%5.8%1.7%
    Dec 2023$27.12B-0.6%76.0%28.0%20.7%
    Dec 2022$27.28B-0.1%79.3%26.9%16.7%
    Dec 2021$27.30B+10.6%75.8%36.3%22.7%
    Dec 2020$24.69B+10.0%81.5%16.5%0.4%
    Dec 2019$22.45B+1.5%79.2%19.1%23.9%
    Dec 2018$22.13B-15.2%78.1%37.1%24.7%
    Dec 2017$26.11B-14.1%83.3%54.1%17.8%
    Dec 2016$30.39BN/A86.0%58.0%44.4%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 1672.9% from the year before. In the quarter ended Sep 2026, net income fell 20.3% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$29.44B$28.75B$27.12B$27.28B$27.30B$24.69B$22.45B$22.13B$26.11B$30.39B
    Cost of revenue$6.23B$6.25B$6.50B$5.66B$6.60B$4.57B$4.67B$4.85B$4.37B$4.26B
    Gross profit$23.21B$22.50B$20.62B$21.62B$20.70B$20.12B$17.77B$17.27B$21.74B$26.13B
    Research and development$6.82B$10.57B$6.87B$5.92B$5.54B$10.89B$9.11B$5.02B$3.73B$5.10B
    Operating income$10.02B$1.66B$7.61B$7.33B$9.92B$4.07B$4.29B$8.20B$14.12B$17.63B
    Net income$8.51B$480.00M$5.61B$4.57B$6.20B$89.00M$5.36B$5.46B$4.64B$13.49B
    EBITDA$13.58B$4.43B$10.50B$8.85B$11.33B$4.13B$7.56B$10.30B$15.93B$19.22B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$8.30B$7.80B$6.96B$7.92B$7.77B$7.08B$6.67B$7.57B$7.54B$6.95B$6.69B$7.11B
    Gross profit$6.73B$6.22B$5.51B$6.30B$6.20B$5.58B$5.13B$5.99B$5.97B$5.41B$5.13B$5.02B
    Operating income$3.46B-$10.39B$2.59B$1.98B$3.33B$2.47B$2.24B$2.45B$888.00M$2.64B-$4.32B$1.61B
    Net income$2.43B-$10.50B$2.02B$2.18B$3.05B$1.96B$1.31B$1.78B$1.25B$1.61B-$4.17B$1.42B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $24.94B exceeded cash and equivalents by $17.37B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$59.02B$58.99B$62.13B$63.17B$67.95B$68.41B$61.63B$63.67B$70.28B$56.98B
    Current assets$18.34B$19.17B$16.09B$14.44B$14.77B$16.00B$30.30B$35.84B$31.82B$19.59B
    Cash and equivalents$7.56B$9.99B$6.08B$5.41B$5.34B$6.00B$11.63B$17.94B$7.59B$8.23B
    Total liabilities$36.41B$39.75B$39.38B$41.96B$46.89B$50.19B$38.98B$42.14B$49.78B$37.61B
    Short-term debt$2.81B$1.81B$1.80B$2.27B$1.52B$2.76B$2.50B$2.75B$2.75B$0
    Long-term debt$22.13B$24.90B$23.19B$22.96B$25.18B$28.64B$22.09B$24.57B$30.80B$26.35B
    Shareholder equity$22.70B$19.33B$22.83B$21.24B$21.07B$18.20B$22.52B$21.39B$20.44B$18.89B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$51.41B$49.36B$56.28B$59.02B$58.53B$55.72B$56.43B$58.99B$54.52B$53.58B$56.29B$62.13B
    Total liabilities$38.45B$37.62B$32.85B$36.41B$37.08B$36.13B$37.35B$39.75B$36.13B$35.38B$38.84B$39.38B
    Cash and equivalents$6.44B$3.18B$7.63B$7.56B$7.33B$5.14B$7.93B$9.99B$5.04B$2.77B$4.72B$6.08B
    Shareholder equity$13.04B$11.83B$23.52B$22.70B$21.54B$19.67B$19.16B$19.33B$18.48B$18.28B$17.54B$22.83B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 94.4% of operating cash flow. Dividends and share repurchases together came to 62.6% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$10.02B$10.83B$8.01B$9.07B$11.38B$8.17B$9.14B$8.40B$11.90B$17.05B
    Capital expenditures$563.00M$523.00M$585.00M$728.00M$579.00M$650.00M$825.00M$924.00M$590.00M$748.00M
    Free cash flow$9.46B$10.30B$7.42B$8.34B$10.80B$7.52B$8.32B$7.48B$11.31B$16.30B
    Dividends paid$4.00B$3.92B$3.81B$3.71B$3.60B$3.45B$3.22B$2.97B$2.73B$2.46B
    Share repurchases$1.92B$1.15B$1.00B$1.40B$546.00M$1.58B$1.75B$2.90B$954.00M$11.00B
    Investing cash flow-$4.79B-$3.45B-$2.27B-$2.47B-$3.13B-$14.62B-$7.82B$14.36B-$16.07B-$11.98B
    Financing cash flow-$7.75B-$3.43B-$5.13B-$6.47B-$8.88B$770.00M-$7.63B-$12.32B$3.39B-$9.72B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$5.04B$3.57B$2.54B$3.33B$4.11B$827.00M$1.76B$2.98B$4.31B$1.32B$2.22B$2.17B
    Capital expenditures$237.00M$140.00M$117.00M$205.00M$147.00M$107.00M$104.00M$147.00M$141.00M$130.00M$105.00M$215.00M
    Free cash flow$4.80B$3.43B$2.43B$3.12B$3.96B$720.00M$1.65B$2.83B$4.17B$1.20B$2.11B$1.95B
    Last 12 quarters

    Frequently Asked Questions About GILD

    What is Gilead Sciences' annual revenue?

    Gilead Sciences reported revenue of $29.44B for the fiscal year ended Dec 31, 2025.

    How fast is Gilead Sciences' revenue growing?

    Revenue was up 2.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.6%.

    Is Gilead Sciences profitable?

    Yes. Gilead Sciences reported net income of $8.51B for the fiscal year ended Dec 31, 2025, with a net margin of 28.9%.

    How much free cash flow does GILD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $10.02B minus capital expenditures of $563.00M produced free cash flow of $9.46B.

    How much debt does Gilead Sciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $22.13B, short-term debt of $2.81B and cash and equivalents of $7.56B.